Yidu Technology (02158) repurchased for 2 consecutive days, spending nearly HK$3 million

The Zhitong Finance App learned that according to the Yidu Technology (2158) announcement, on December 4, the company repurchased 181,000 shares at an average price of HK$5.15 per share, with a repurchase amount of over HK$930,000. It has been repurchased for two consecutive days. In total, about 573,000 shares have been repurchased, with a cumulative repurchase amount of nearly HK$3 million.

Since September 26, the stock has been repurchased 12 times, with a cumulative repurchase amount of over HK$25 million.

According to the news, Yidu Technology recently released its 2026 interim results and held a performance conference. The report shows that during the reporting period, Yidu Technology's business maintained healthy growth, with total revenue reaching RMB 358 million, an increase of 8.7% over the previous year. The company's profit quality and operating efficiency have made a significant leap forward: the adjusted EBITDA of the current business is about RMB 54 million, which is double that of the same period last year, and the balance of profit and loss is almost at the level of accounting statements. This key financial milestone was reached about a year earlier than previously anticipated by the company's management.

The company's management pointed out at the performance meeting that its large-scale medical model technology has entered a new stage of “more flowering and large-scale implementation”. This is mainly reflected in three dimensions: First, the AI platform has been deeply deployed in more than 30 of the top three hospitals across the country. Among them, the “Copilot” auxiliary tool for clinicians has achieved an average of nearly 1,000 high-frequency calls per day and has been integrated into the actual workflow; second, the enabling effect on key specialties such as oncology is remarkable, and the diagnostic accuracy of the TNM phased evaluation agent it has developed (such as the T-stage accuracy rate increased from 58% to 90%) has reached the level of chief physicians; third, experiments will be scarce by creating “digital aliases” for top doctors. A wider range of expert experience Be able to explore new models of medical wisdom transmission and inclusion at the grassroots level.

At the capital market level, brokerage institutions continue to send positive signals. Everbright Securities pointed out in a follow-up research report that Yidu Technology continues to break through in the field of AI medical innovation. Its medical model has initially built a closed loop of “data+algorithm+scenario”, which is accelerating the implementation of the technology in multiple scenarios. Citi also released a report to maintain the company's “buy” rating, with a target price of HK$10, fully acknowledging its core competitiveness and growth potential on the AI healthcare circuit.

As of today's close, Yidu Technology's stock price was HK$5.15, up 0.98%.